We are live on ! Find out more
LPC

Lion Point Capital Portfolio holdings

AUM $16.7M
1-Year Est. Return 119.35%
This Fund
S&P 500
This Quarter Est. Return
-4.5%
1 Year Est. Return
+119.35%
3 Year Est. Return
+204.43%
5 Year Est. Return
+220.32%
10 Year Est. Return
+1,396.08%
AUM
$16.7M
AUM Growth
-$2.59M
Cap. Flow
-$492K
Cap. Flow %
-2.94%
Top 10 Hldgs %
54.62%
Holding
39
New
–
Increased
3
Reduced
–
Closed
4

Top Buys

1
HUMA icon
Humacyte
HUMA
+$156K
2
CMPS
Compass Pathways
CMPS
+$148K
3
MIST icon
Milestone Pharmaceuticals
MIST
+$114K

Top Sells

1
DAWN
Day One Biopharmaceuticals
DAWN
+$391K
2
VTYX
Ventyx Biosciences
VTYX
+$375K
3
NERV icon
Minerva Neurosciences
NERV
+$141K
4
MRSN
Mersana Therapeutics
MRSN
+$2.89K

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRAX icon
1
Praxis Precision Medicines
PRAX
$8.59B
$1.43M 8.57%
4,450
– –
MLTX icon
2
MoonLake Immunotherapeutics
MLTX
$1.59B
$1.26M 7.52%
67,500
– –
RPRX icon
3
Royalty Pharma
RPRX
$25.9B
$1.03M 6.14%
21,400
– –
MIST icon
4
Milestone Pharmaceuticals
MIST
$154M
$976K 5.83%
820,000
+65,000
+9% +$114K
GERN icon
5
Geron
GERN
$911M
$861K 5.15%
578,000
– –
SNDX icon
6
Syndax Pharmaceuticals
SNDX
$2.01B
$841K 5.03%
36,000
– –
ARDX icon
7
Ardelyx
ARDX
$1.27B
$771K 4.61%
128,650
– –
FENC icon
8
Fennec Pharmaceuticals
FENC
$363M
$691K 4.13%
112,434
– –
BNTC icon
9
Benitec Biopharma
BNTC
$435M
$660K 3.95%
62,000
– –
SRPT icon
10
Sarepta Therapeutics
SRPT
$1.82B
$620K 3.71%
28,500
– –
IRON icon
11
Disc Medicine
IRON
$2.81B
$518K 3.1%
8,100
– –
CUE icon
12
Cue Biopharma
CUE
$117M
$506K 3.03%
73,428
– –
CMPS
13
Compass Pathways
CMPS
$1.68B
$442K 2.64%
80,000
+22,000
+38% +$148K
BHVN icon
14
Biohaven
BHVN
$2.13B
$437K 2.61%
51,700
– –
LNTH icon
15
Lantheus
LNTH
$6.84B
$417K 2.49%
5,500
– –
JSPR icon
16
Jasper Therapeutics
JSPR
$21.7M
$407K 2.44%
465,000
– –
HUMA icon
17
Humacyte
HUMA
$178M
$394K 2.36%
650,000
+150,000
+30% +$156K
VTRS icon
18
Viatris
VTRS
$20.2B
$374K 2.24%
27,700
– –
KURA icon
19
Kura Oncology
KURA
$967M
$374K 2.24%
46,000
– –
BBIO icon
20
BridgeBio Pharma
BBIO
$15.7B
$371K 2.22%
5,000
– –
DYN icon
21
Dyne Therapeutics
DYN
$3.76B
$326K 1.95%
18,000
– –
RCKT icon
22
Rocket Pharmaceuticals
RCKT
$372M
$308K 1.84%
86,000
– –
PCRX icon
23
Pacira BioSciences
PCRX
$1.01B
$305K 1.82%
13,500
– –
EWTX icon
24
Edgewise Therapeutics
EWTX
$4.11B
$287K 1.71%
9,100
– –
MLYS icon
25
Mineralys Therapeutics
MLYS
$2.39B
$284K 1.7%
10,500
– –
1
2

Similar funds

PA
PPM America Chicago, Illinois $16.6M AUM 31.99% 1-Year Est. Return
PA
Prossimo Advisors San Luis Obispo, California $16.4M AUM 14% 1-Year Est. Return
SR
Swiss Re Zurich, Switzerland $16.4M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
SRA
Summit Rock Advisors New York $16M AUM
CP
Covalent Partners Concord, Massachusetts $17.6M AUM 2.91% 1-Year Est. Return
B
BP London, United Kingdom $17.7M AUM 12.34% 1-Year Est. Return
CVV
Curative Ventures V Dallas, Texas $15.6M AUM 52.53% 1-Year Est. Return